专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08470548B2 Diagnosis of depression 有权
标题翻译：抑郁症诊断
公开(公告)号：US08470548B2
公开(公告)日：2013-06-25
申请号：US13335402
申请日：2011-12-22
申请人： Per Svenningsson , Paul Greengard
发明人： Per Svenningsson , Paul Greengard
IPC分类号： G01N33/53 , G01N33/567 , G01N33/542 , C12Q1/68
CPC分类号： C12Q1/6876 , A01K67/0275 , A01K67/0276 , A01K2217/052 , A01K2217/075 , A01K2217/20 , A01K2227/105 , A01K2267/0356 , A61K49/0008 , C07K14/4721 , C07K2319/41 , C12N15/8509 , C12N2830/003 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , G01N33/68 , G01N33/6896 , G01N33/942 , G01N2333/46 , G01N2500/00 , G01N2500/04 , G01N2500/10 , G01N2800/30 , G01N2800/304 , Y10T436/143333
摘要： The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.
摘要翻译：本发明涉及p11作为药物靶的用途以及用于诊断，治疗和发展p11 / 5-HT受体相关病症的工具。本发明还涉及p11敲除动物以及p11转基因动物及其作为开发新型精神治疗剂的模型的用途，以及诊断，预防和治疗p11 / 5-HT受体相关病症的方法。

2. 发明申请

US20100143361A1 METHODS FOR THE TREATMENT OF A-BETA RELATED DISORDERS AND COMPOSITIONS THEREFOR 有权
标题翻译：用于治疗甲型相关疾病的方法及其组合物
公开(公告)号：US20100143361A1
公开(公告)日：2010-06-10
申请号：US12447080
申请日：2007-10-24
申请人： Marc Flajolet , Paul Greengard
发明人： Marc Flajolet , Paul Greengard
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/53 , A61K31/713 , A61K31/7088 , A61K31/415 , A61K31/405 , A61P25/28
CPC分类号： A61K31/44 , A61K31/40 , A61K31/70
摘要： The invention provides methods for treating Aβ peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.
摘要翻译：本发明提供了治疗A＆Bgr的方法。肽相关疾病如阿尔茨海默氏病包括向有需要的患者施用治疗有效量的CK1调节剂。

3. 发明申请

US20090233993A1 COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF 审中-公开
标题翻译：用于抑制GSK3活性的组合物和方法及其用途
公开(公告)号：US20090233993A1
公开(公告)日：2009-09-17
申请号：US12399850
申请日：2009-03-06
申请人： Huaxi Xu , Limin Li , Francesca-Fang Liao , Yun-wu Zhang , Wu-bo Li , Paul Greengard , Stanley N. Cohen
发明人： Huaxi Xu , Limin Li , Francesca-Fang Liao , Yun-wu Zhang , Wu-bo Li , Paul Greengard , Stanley N. Cohen
IPC分类号： A61K31/7088 , C07H21/00 , C12N15/74 , C12P21/02 , C07K2/00 , C12N5/06 , A61P25/28 , G01N33/567
CPC分类号： C07K14/705 , A61K38/00 , G01N2333/91205 , G01N2800/2821
摘要： Disclosed herein are compositions and methods relating to peptides. The peptides can inhibit amyloid beta (Aβ) generation and reduce GSK-3 activities. Further provided are compositions and methods for treating or preventing, for example, Alzheimer's disease, cancer, and diabetes.
摘要翻译：本文公开了与肽相关的组合物和方法。肽可以抑制淀粉样蛋白β（Abeta）的产生并降低GSK-3活性。还提供了用于治疗或预防例如阿尔茨海默病，癌症和糖尿病的组合物和方法。

4. 发明授权

US09157906B2 Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain 有权
公开(公告)号：US09157906B2
公开(公告)日：2015-10-13
申请号：US12951775
申请日：2010-11-22
申请人： Paul Greengard , David Repaske , Gretchen Snyder
发明人： Paul Greengard , David Repaske , Gretchen Snyder
IPC分类号： C12Q1/00 , G01N33/573 , G01N33/50 , C12Q1/44 , G01N33/94 , A61K31/00 , A61K31/137 , A61K31/55 , A61K49/00
CPC分类号： G01N33/5041 , A61K31/00 , A61K31/137 , A61K31/55 , A61K49/0008 , C12Q1/44 , G01N33/9413 , G01N2333/916 , G01N2500/04 , G01N2800/2835
摘要： The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.

5. 发明申请

US20140107104A1 COMBINATION MEDICINE FOR TREATMENT OF DEPRESSION 审中-公开
标题翻译：用于治疗呕吐的组合药物
公开(公告)号：US20140107104A1
公开(公告)日：2014-04-17
申请号：US14006172
申请日：2012-03-22
申请人： Akinori Nishi , Katsunori Kobayashi , Tsuyoshi Miyakawa , Paul Greengard
发明人： Akinori Nishi , Katsunori Kobayashi , Tsuyoshi Miyakawa , Paul Greengard
IPC分类号： A61K31/55 , G01N33/50 , C12Q1/68 , A61K31/135
CPC分类号： A61K31/55 , A61K31/135 , A61K31/138 , A61K45/06 , C12Q1/68 , G01N33/5023 , G01N33/5088 , A61K2300/00
摘要： The present invention provides a combination medicine for treatment of depression, comprising a combination of (A1) an antidepressant and either (B1) a dopamine D1 receptor agonist or (C1) a dopamine D1 receptor antagonist; and a method for screening for an antidepressant that in combination with a dopamine D1 receptor agonist provides an improvement in treatment of depression, the method comprising the steps of: administering, to a mammal, (A2) a compound having an antidepressant action and (B1) a dopamine D1 receptor agonist, and detecting a greater increase in depression-related gene expression, dopamine D1 receptor expression and/or dopamine D1 receptor signaling in comparison with the case where (A2) the compound having an antidepressant action or (B1) the dopamine D1 receptor agonist is administered.
摘要翻译：本发明提供了治疗抑郁症的组合药物，其包含（A1）抗抑郁药和（B1）多巴胺D1受体激动剂或（C1）多巴胺D1受体拮抗剂的组合; 以及与多巴胺D1受体激动剂组合提供抗抑郁药治疗改善的抗抑郁药的方法，所述方法包括以下步骤：向哺乳动物施用（A2）具有抗抑郁作用的化合物和（B1 ）多巴胺D1受体激动剂，并且与（A2）具有抗抑郁作用的化合物或（B1）的情况相比，检测抑制相关基因表达，多巴胺D1受体表达和/或多巴胺D1受体信号传导的更大增加给予多巴胺D1受体激动剂。

6. 发明申请

US20110071049A1 METHODS AND COMPOSITIONS FOR TRANSLATIONAL PROFILING AND MOLECULAR PHENOTYPING 审中-公开
标题翻译：用于翻译分析和分子鉴定的方法和组合
公开(公告)号：US20110071049A1
公开(公告)日：2011-03-24
申请号：US12918761
申请日：2009-03-12
申请人： Nathaniel Heintz , Paul Greengard , Myriam Heiman , Anne Schaefer , Joseph P. Doyle , Joseph D. Dougherty
发明人： Nathaniel Heintz , Paul Greengard , Myriam Heiman , Anne Schaefer , Joseph P. Doyle , Joseph D. Dougherty
IPC分类号： C40B30/04 , C40B40/08 , C40B30/00 , C12Q1/68 , C12N15/63
CPC分类号： C12N15/62 , A01K67/0278 , A01K2217/206 , A01K2227/105 , A01K2267/01 , C12N15/111 , C12N2320/12 , G01N33/5023 , G01N33/5058 , G01N2800/285
摘要： Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample.
摘要翻译：提供了用于特定组织，细胞和感兴趣的细胞亚型的翻译分型和分子表型的方法和组合物。本文提供的方法有助于分析异种样品中存在的所选子集中的基因表达。

7. 发明授权

US07320785B2 Compositions and methods for modulation of DARPP-32 phosphorylation 有权
标题翻译：用于调节DARPP-32磷酸化的组合物和方法
公开(公告)号：US07320785B2
公开(公告)日：2008-01-22
申请号：US10218137
申请日：2002-08-12
申请人： Paul Greengard , Per Svenningsson , Sergey V. Rakhilin , Natalia Starkova
发明人： Paul Greengard , Per Svenningsson , Sergey V. Rakhilin , Natalia Starkova
IPC分类号： A61K49/00 , G01N33/53 , G01N33/567
CPC分类号： C12N9/16 , C12Y301/03016 , G01N33/566 , G01N33/6872 , G01N33/6896 , G01N2500/02 , G01N2500/04
摘要： The present invention provides methods and compositions for modulating the phosphorylation of DARPP-32 in a serotonergic receptor intracellular signaling pathway. The invention provides methods and compositions for modulating the activities of DARPP-32, casein kinase 1 (CK1), cyclin-dependent kinase 5 (Cdk5), AMPA receptors, protein phosphatase-1 (PP-1), protein phosphatase 2C (PP2C), protein phosphatase 2B (PP2B) and/or protein phosphatase 2A (PP2A) in cells or tissues. The invention provides methods of treating serotonergic intracellular signaling pathway disorders, e.g., depression. The invention provides methods of treating dopamine-related disorders. The invention provides methods of identifying agents that modulate the activities of serotonergic receptor intracellular signaling molecules, DARPP-32, casein kinase 1, cyclin-dependent kinase 5, AMPA receptors, protein phosphatase-1, protein phosphatase 2C, protein phosphatase 2B and/or protein phosphatase 2A, for use in such treatments. The invention also provides methods of modulating phosphorylation-dependent activation of AMPA receptors for use in such treatments.
摘要翻译：本发明提供用于调节血清素受体细胞内信号传导途径中DARPP-32的磷酸化的方法和组合物。本发明提供了用于调节DARPP-32，酪蛋白激酶1（CK1），细胞周期蛋白依赖性激酶5（Cdk5），AMPA受体，蛋白磷酸酶-1（PP-1），蛋白磷酸酶2C（PP2C），蛋白磷酸酶2B（PP2B）和/或蛋白磷酸酶2A（PP2A）在细胞或组织中。本发明提供治疗5-羟色胺能细胞内信号传导途径障碍（例如抑郁症）的方法。本发明提供了治疗多巴胺相关疾病的方法。本发明提供了鉴定调节血清素受体细胞内信号传导分子，DARPP-32，酪蛋白激酶1，细胞周期蛋白依赖性激酶5，AMPA受体，蛋白磷酸酶-1，蛋白磷酸酶2C，蛋白磷酸酶2B和/或蛋白质磷酸酶2A，用于这种治疗。本发明还提供调节用于这种治疗的AMPA受体的磷酸化依赖性活化的方法。

8. 发明授权

US06429010B1 DNA encoding the human synapsin III gene and uses thereof 失效
标题翻译：编码人突触蛋白III基因的DNA及其用途
公开(公告)号：US06429010B1
公开(公告)日：2002-08-06
申请号：US09129668
申请日：1998-08-05
申请人： Paul Greengard , Barbara Porton , Hung-Teh Kao
发明人： Paul Greengard , Barbara Porton , Hung-Teh Kao
IPC分类号： C12N1500
CPC分类号： C07K14/47 , A61K38/00
摘要： A new synapsin protein, designated synapsin III, its amino acid sequence, and its human gene have been isolated and characterized. Furthermore, isoforms of synapsin III, e.g., synapsin IIIa, IIIb and IIIc, and have isolated and characterized, and cDNA encoding these isoforms has also been isolated and characterized. The synapsin III gene is located on human chromosome 22, in the vicinity of a region previously identified as a susceptibility locus for schizophrenia. The information and experimental tools provided by this discovery can be used to generate new therapeutic agents or diagnostic assays for this new protein, its associated mRNA or its associated genomic DNA. Due to its role in neurotransmission and synaptogenesis, isoforms of synapsin III are associated with the symptoms of psychiatric diseases, especially schizophrenia.
摘要翻译：已经分离并表征了新的突触蛋白，命名为突触蛋白III，其氨基酸序列及其人基因。此外，已经分离并表征了突触蛋白III的同种型，例如突触蛋白IIIa，IIIb和IIIc，并且已经分离和表征，以及编码这些同种型的cDNA。突触素III基因位于人类染色体22上，在先前鉴定为精神分裂症易感基因座的区域附近。该发现提供的信息和实验工具可用于为该新蛋白，其相关mRNA或其相关基因组DNA产生新的治疗剂或诊断测定。由于其在神经传递和突触发生中的作用，突触素III的同种型与精神疾病，特别是精神分裂症的症状有关。

9. 发明授权

US10336757B2 Treatment of neurodegenerative diseases through inhibition of HSP90 有权
公开(公告)号：US10336757B2
公开(公告)日：2019-07-02
申请号：US12307063
申请日：2007-07-02
申请人： Gabriela Chiosis , Paul Greengard , Fei Dou , Wenjie Luo , Huazhong He , Danuta Zatorska
发明人： Gabriela Chiosis , Paul Greengard , Fei Dou , Wenjie Luo , Huazhong He , Danuta Zatorska
IPC分类号： A01N43/90 , A61K31/52 , A01N43/54 , C07D239/42 , C07D401/04 , A01N43/50 , A61K31/415 , A01N43/30 , A61K31/36 , C07D473/40
摘要： Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.

10. 发明授权

US09605041B2 Regulatory proteins and inhibitors 有权
公开(公告)号：US09605041B2
公开(公告)日：2017-03-28
申请号：US13367049
申请日：2012-02-06
申请人： Paul Greengard , Wenjie Luo , Gen He , Peng Li , Lawrence Wennogle
发明人： Paul Greengard , Wenjie Luo , Gen He , Peng Li , Lawrence Wennogle
IPC分类号： C07K16/40 , C12N15/113 , C07K14/47 , A01K67/027 , A61K39/00 , G01N33/68 , A61K31/506 , C07K16/18 , C12Q1/68 , A61K38/00
CPC分类号： C07K14/4705 , A01K67/0275 , A01K2207/05 , A01K2217/058 , A01K2217/15 , A01K2217/203 , A01K2227/105 , A01K2267/0312 , A61K31/506 , A61K38/00 , A61K39/0007 , C07K16/18 , C12N15/113 , C12Q1/6827 , C12Q1/686 , G01N33/6896 , G01N2800/2821
摘要： The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates γ-secretase to produce β-amyloid protein (Aβ). Deposition of Aβ has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of Aβ.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式